UNITED LAB (03933) Flags 24.8% Profit Drop for FY2025 to Around RMB2.00 Billion

Bulletin Express03-13

Hong Kong, 12 Mar 2026—The United Laboratories International Holdings Limited (UNITED LAB, 03933) issued a profit warning indicating that unaudited consolidated net profit for the year ended 31 Dec 2025 is expected to be about RMB2.00 billion, down from RMB2.66 billion in 2024—a year-on-year decline of roughly 24.8%.

The company cited lower market prices for its Intermediate Products and Bulk Medicine as the principal drag on earnings:

• Intermediate Products: segment profit fell by approximately RMB1.60 billion. • Bulk Medicine: segment profit contracted by roughly RMB0.40 billion.

These setbacks were partly offset by stronger performance in Finished Products, where segment profit rose by about RMB1.40 billion. Within this increase, a license-fee contribution of around RMB1.30 billion from Novo Nordisk A/S played a dominant role.

Management noted that the figures are based on internal management accounts prepared under Hong Kong Financial Reporting Standards and have neither been reviewed by the audit committee nor audited. Final audited results will be released in the forthcoming 2025 annual results announcement and annual report.

The board advised shareholders and potential investors to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196290897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 12:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196290897","market":"us","top_or_hot":-1,"title":"UNITED LAB (03933) Flags 24.8% Profit Drop for FY2025 to Around RMB2.00 Billion","media":"Bulletin Express","content":"<p>Hong Kong, 12 Mar 2026—The United Laboratories International Holdings Limited (UNITED LAB, 03933) issued a profit warning indicating that unaudited consolidated net profit for the year ended 31 Dec 2025 is expected to be about RMB2.00 billion, down from RMB2.66 billion in 2024—a year-on-year decline of roughly 24.8%.</p>\n<p>The company cited lower market prices for its Intermediate Products and Bulk Medicine as the principal drag on earnings:</p>\n<p>• Intermediate Products: segment profit fell by approximately RMB1.60 billion.  \n• Bulk Medicine: segment profit contracted by roughly RMB0.40 billion.</p>\n<p>These setbacks were partly offset by stronger performance in Finished Products, where segment profit rose by about RMB1.40 billion. Within this increase, a license-fee contribution of around RMB1.30 billion from Novo Nordisk A/S played a dominant role.</p>\n<p>Management noted that the figures are based on internal management accounts prepared under Hong Kong Financial Reporting Standards and have neither been reviewed by the audit committee nor audited. Final audited results will be released in the forthcoming 2025 annual results announcement and annual report.</p>\n<p>The board advised shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB (03933) Flags 24.8% Profit Drop for FY2025 to Around RMB2.00 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB (03933) Flags 24.8% Profit Drop for FY2025 to Around RMB2.00 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 12:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 12 Mar 2026—The United Laboratories International Holdings Limited (UNITED LAB, 03933) issued a profit warning indicating that unaudited consolidated net profit for the year ended 31 Dec 2025 is expected to be about RMB2.00 billion, down from RMB2.66 billion in 2024—a year-on-year decline of roughly 24.8%.</p>\n<p>The company cited lower market prices for its Intermediate Products and Bulk Medicine as the principal drag on earnings:</p>\n<p>• Intermediate Products: segment profit fell by approximately RMB1.60 billion.  \n• Bulk Medicine: segment profit contracted by roughly RMB0.40 billion.</p>\n<p>These setbacks were partly offset by stronger performance in Finished Products, where segment profit rose by about RMB1.40 billion. Within this increase, a license-fee contribution of around RMB1.30 billion from Novo Nordisk A/S played a dominant role.</p>\n<p>Management noted that the figures are based on internal management accounts prepared under Hong Kong Financial Reporting Standards and have neither been reviewed by the audit committee nor audited. Final audited results will be released in the forthcoming 2025 annual results announcement and annual report.</p>\n<p>The board advised shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1196290897","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196290897","pubTimestamp":1773375739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 12 Mar 2026—The United Laboratories International Holdings Limited (UNITED LAB, 03933) issued a profit warning indicating that unaudited consolidated net profit for the year ended 31 Dec...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药(03933)2025财年利润下降24.8%至约人民币20亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"Hong Kong, 12 Mar 2026—The United Laboratories International Holdings Limited (UNITED LAB, 03933) issued a profit warning indicating that unaudited consolidated net profit for the year ended 31 Dec 2025 is expected to be about RMB2.00 billion, down from RMB2.66 billion in 2024—a year-on-year decline of roughly 24.8%.\nThe company cited lower market prices for its Intermediate Products and Bulk Medicine as the principal drag on earnings:\n• Intermediate Products: segment profit fell by approximately RMB1.60 billion.  \n• Bulk Medicine: segment profit contracted by roughly RMB0.40 billion.\nThese setbacks were partly offset by stronger performance in Finished Products, where segment profit rose by about RMB1.40 billion. Within this increase, a license-fee contribution of around RMB1.30 billion from Novo Nordisk A/S played a dominant role.\nManagement noted that the figures are based on internal management accounts prepared under Hong Kong Financial Reporting Standards and have neither been reviewed by the audit committee nor audited. Final audited results will be released in the forthcoming 2025 annual results announcement and annual report.\nThe board advised shareholders and potential investors to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196290897","isCrawlerRequest":true}